Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,
Globus Medical to acquire Nevro for $5.85 per share
EST Globus Medical (GMED) to acquire Nevro (NVRO) for $5.85 per share Published first on TheFly – the ultimate source for real-time,
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Jefferies maintains Buy on Globus Medical, target at $105
Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO),
Globus Medical to buy California life sciences firm for $250M
The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth. Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain for $250 million in cash.
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.
Nevro upgraded to Neutral from Underweight at Piper Sandler
Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the ...
TMCnet12h
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
Stifel maintains GMED buy rating, $92 target amid NVRO buyout
Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...
Globus acquisition of Nevro ‘fairly low-risk bet,’ says BTIG
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...
TMCnet13h
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders
Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
Zacks.com on MSN14d
Here's Why you Should Add Nevro Stock to Your Portfolio Now
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.
U.S.-Canada tariffs no threat to this stock
The U.S. 25 per cent tariffs on a range of Canadian goods and 10 per cent on energy exports from Canada, goes in to effect ...
EnviroGold Global Achieves Major Process Optimisation Breakthrough, Doubling Project Economics and Enhancing Environmental Performance
These developments further strengthen EnviroGold’s first mover advantage and accelerate the commercialisation of its highly efficient and scalable solution for processing mine tailings.